RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

20250 citationsJournal Articlegold Open Access

Authors

Makoto Nishio · The Cancer Institute Hospital

Takashi Seto · National Hospital Organization Kyushu Cancer Center

M. Reck · German Center for Lung Research

E.B. Garon

Kazuto Nishio · Kindai University

Kazuo Kasahara · Nippon Medical School Hospital

K. Nishino · Osaka International Cancer Institute

Abstract

RELAY+ revealed a favorable benefit-risk profile for RAM plus GEF in East Asian patients with untreated <i>EGFR</i>-mutated metastatic NSCLC, supporting RAM plus GEF as an alternative first-line treatment option, particularly in those with an L858R mutation.

Topics & Keywords

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes

Publication Details

Published in: JTO Clinical and Research Reports

Volume 6, Issue 12, pp. 100912-100912

DOI: 10.1016/j.jtocrr.2025.100912

Field-Weighted Citation Impact: 0.00

Command Palette

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Authors

Abstract

Topics & Keywords

Publication Details